A Phase 2 interventional study of ABI-007 and Docetaxel in Metastatic Breast Cancer, sponsored by Celgene. Completed at 1 site in Ukraine. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 16th largest by enrollment, is one of 6 that started in 2005, is one of 67 in phase 2, and was the 9th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Henan Cancer Hospital · Sites in China
Ages 18–70
University of Illinois at Chicago · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 79 · Phase 3 11 · Phase 4 4
First in 2001; this study’s year is marked. 6 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 108 interventional studies. Of the 66 that completed or were terminated, 41 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2005, is one of 23 in phase 2, and was the 8th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
3 of the studies testing Albumin-Bound Paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420454Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Neoadjuvant Treatment of Breast Cancer | 2027-06-10 |
| NCT05420467Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Adjuvant Treatment of Breast Cancer | 2027-07-10 |
| NCT05287308Chinese Academy of Medical SciencesAdjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was an open-label study conducted comparing the toxicity and antitumor activity of ABI-007 (Abraxane®, nab®-paclitaxel) to docetaxel (Taxotere).
This was an open-label, randomized study to compare the following regimens with respect to toxicity and antitumor activity:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients had to meet the following criteria to be eligible for the study:
Patient had the following blood counts at Baseline:
Patient had the following baseline blood chemistry levels:
Exclusion Criteria:
Patients who met any of the following criteria were excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABI-007 300 mg/m\^2 administered once every third week (q3w).
Drug: ABI-007
ABI-007 100 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
Drug: ABI-007
ABI-007 150 mg/m\^2 once weekly for 3 weeks followed by 1 week of rest
Drug: ABI-007
Docetaxel (Taxotere) 100 mg/m\^2 administered once every third week (q3w).
Drug: Docetaxel
ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
Also known as: Abraxane®, nab®-paclitaxel
Docetaxel dosed q3w at 100 mg/m\^2
Also known as: Taxotere
Percentage of Participants Showing an Overall Response As Assessed by the Independent Radiology Reader and by the Investigator
Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is \>= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.
Time frame: Day 1 up to 95 weeks
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response
Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately
Time frame: Day 1 up to 95 weeks
Kaplan-Meier Estimates for Progression-free Survival (PFS)
PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: Day 1 up to 95 weeks
Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression
Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.
Time frame: Day 1 - 95 weeks
Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression
Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.
Time frame: Day 1 - 95 weeks
Kaplan-Meier Estimate for Overall Survival (OS)
Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).
Time frame: Day 1 to 221 weeks
Participants With Treatment-Emergent, Treatment-Related Adverse Events
Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.
Time frame: Day 1 up to 125 weeks
Nadir of Myelosuppression (Over All Cycles) as Measured by Absolute Neutrophils (ANC), White Blood Cells (WBC) and Platelet Counts
Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.
Time frame: Day 1 up to 125 weeks
Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts
Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.
Time frame: Day 1 up to 125 weeks
| Milestone | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Started | 76 | 76 | 74 | 74 |
| At least one response assessment | 73 | 76 | 73 | 70 |
| Completed | 39 | 49 | 39 | 29 |
| Not completed | 37 | 27 | 35 | 45 |
| Withdrew: Still on treatment | 2 | 3 | 5 | 1 |
| Withdrew: Unacceptable toxicity | 10 | 5 | 12 | 16 |
| Withdrew: Adverse event | 0 | 1 | 2 | 2 |
| Withdrew: Physician decision | 7 | 5 | 6 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 18 | 13 | 9 | 13 |
Percentage of participants who achieve an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms. A partial response (PR) is \>= 30% decrease in the sum of the longest diameters of target lesion. PR was also recorded when all measurable disease has completely disappeared, but a non-measurable component (ie, ascites) is still present but not progressing. Overall response (ORR) = CR+PR.
| percentage of participants | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Independent reader assessed ORR | 37 (26.0 to 47.7) | 45 (33.6 to 55.9) | 49 (37.3 to 60.0) | 35 (24.3 to 46.0) |
| Investigator assessed ORR | 46 (34.8 to 57.3) | 63 (52.3 to 74.0) | 74 (64.4 to 84.3) | 39 (28.1 to 50.3) |
Known as the disease control rate, this outcome measures the percentage of participants with stable disease for 16 weeks or more, or had a confirmed complete or partial response (see outcome #1 for confirmed response definitions). Assessments made by independent radiology and by investigators are reported separately
| percentage of participants | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Independent Assessed SD Disease Control | 68 (58.0 to 78.9) | 75 (65.3 to 84.7) | 80 (70.6 to 88.9) | 58 (46.9 to 69.3) |
| Investigator Assessed Disease Control | 72 (62.3 to 82.4) | 83 (74.4 to 91.4) | 91 (83.9 to 97.2) | 69 (58.4 to 79.5) |
PFS was defined as the time from the date of randomization to the start of disease progression (PD) or patient death (any cause), whichever occurred first. Patients without disease progression were censored at the last time the patient was known to be progression-free. Patients who initiated new anticancer therapy prior to documented progression or death were censored at the start of new therapy. Disease progression was assessed separately by investigators and by an independent radiologist. Both assessments are offered. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000). PD for target lesions is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| months | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Independent Assessment for PFS | 11.0 (7.3 to 15.0) | 12.8 (9.0 to 14.7) | 12.9 (10.9 to 16.6) | 7.5 (7.2 to 9.0) |
| Investigator Assessment for PFS | 10.9 (8.9 to 14.6) | 7.5 (7.2 to 9.3) | 14.6 (10.0 to 18.9) | 7.8 (6.3 to 11.0) |
Duration of response was measured as the progression-free survival on patients with confirmed response. The independent radiology assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.
| months | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Kaplan-Meier Estimates for Duration of Response Based on Independent Radiology Assessment of Response and Progression | 13.0 (11.2 to 23.9) | 13.2 (11.3 to 14.9) | 15.1 (10.9 to 16.7) | 9.0 (7.5 to 14.8) |
Duration of response was measured as the progression-free survival on patients with confirmed response. The investigator assessment is offered here. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 (Therasse, 2000) and is defined in outcome #1. Progression-free survival is defined in outcome #3.
| months | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Kaplan-Meier Estimates for Duration of Response Based on Investigator Assessment of Response and Progression | 12.9 (10.3 to 19.4) | 9.2 (7.4 to 12.4) | 14.8 (12.8 to 19.2) | 15.1 (11.0 to 17.6) |
Participant survival was defined as the date of randomization to the date of death. Participants that were alive at the time of analysis were censored at the last known time that the participant was alive. The final analysis of mature overall survival was conducted after 2 years of follow-up (data cutoff date 31 Jan 2010).
| months | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Kaplan-Meier Estimate for Overall Survival (OS) | 27.7 (21.7 to 38.9) | 22.2 (16.9 to 29.4) | 33.8 (29.1 to 41.3) | 26.6 (19.0 to 31.3) |
Maximal degree of myelosuppression is represented by the nadir in absolute neutrophil (ANC), white blood cell (WBC), and platelet measurements over all treatment cycles.
| 10^9/L | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| ANC | 1.21 ± 1.004 | 1.51 ± 0.960 | 1.11 ± 0.628 | 0.38 ± 0.339 |
| WBC | 2.88 ± 1.187 | 3.15 ± 1.228 | 2.68 ± 0.817 | 1.60 ± 0.726 |
| Platelet | 182.1 ± 59.16 | 192.1 ± 57.82 | 172.6 ± 46.39 | 161.8 ± 49.06 |
Summary of participants who had treatment-emergent that were treatment-related in the opinion of the investigator, and summarized in a variety of categories. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.
| participants | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| >= 1 adverse event (AE) | 75 | 75 | 73 | 73 |
| >=1 treatment-related AE | 74 | 72 | 73 | 72 |
| >=1 serious AE | 14 | 12 | 11 | 56 |
| >=1 treatment-related serious AE | 13 | 5 | 8 | 55 |
| >=1 severe (grade 3-5) treatment-related AE | 47 | 30 | 49 | 71 |
| Grade 3-5 Neutropenia | 33 | 19 | 33 | 68 |
| Grade 3-5 Febrile neutropenia | 1 | 1 | 1 | 8 |
| Grade 3-5 Sensory neuropathy | 16 | 7 | 16 | 9 |
| >=1 AE with outcome of death | 0 | 1 | 2 | 2 |
| >=1 treatment-related AE with outcome of death | 0 | 0 | 0 | 2 |
| >=1 treatment-related AE drug discontinued | 10 | 5 | 12 | 16 |
| >=1 treatment-related AE drug dosage reduced | 14 | 13 | 35 | 21 |
| >=1 treatment-related AE drug interrupted | 1 | 1 | 0 | 1 |
Maximal degree of myelosuppression is represented by the nadir in hemoglobin (Hb) measurements over all treatment cycles.
| g/L | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| Nadir of Myelosuppression (Over All Cycles) as Measured by Hemoglobin (Hb) Counts | 112.1 ± 10.58 | 106.7 ± 10.72 | 105.6 ± 11.31 | 107.1 ± 13.39 |
Collected over Day 1 up to 125 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABI-007 300 mg/m^2 q3w | — | 14/76 (18.4%) | 75/76 (98.7%) |
| ABI-007 100 mg/m^2 Weekly | — | 12/76 (15.8%) | 75/76 (98.7%) |
| ABI-007 150 mg/m^2 Weekly | — | 11/74 (14.9%) | 73/74 (98.6%) |
| Docetaxel 100 mg/m^2 q3w | — | 56/74 (75.7%) | 73/74 (98.6%) |
| Event | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 10/76 | 2/76 | 4/74 | 52/74 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/76 | 1/76 | 1/74 | 8/74 |
| ErysipelasInfections and infestations | 0/76 | 2/76 | 0/74 | 1/74 |
| AnaemiaBlood and lymphatic system disorders | 0/76 | 0/76 | 1/74 | 0/74 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/76 | 0/76 | 0/74 | 1/74 |
| DiarrhoeaGastrointestinal disorders | 0/76 | 0/76 | 0/74 | 1/74 |
| GastritisGastrointestinal disorders | 0/76 | 0/76 | 0/74 | 1/74 |
| Chronic sinusitisInfections and infestations | 0/76 | 0/76 | 1/74 | 0/74 |
| Cardiopulmonary failureCardiac disorders | 0/76 | 1/76 | 1/74 | 0/74 |
| Body temperature increasedInvestigations | 0/76 | 0/76 | 0/74 | 1/74 |
| Event | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 Weekly | Docetaxel 100 mg/m^2 q3w |
|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 51/76 | 59/76 | 59/74 | 52/74 |
| NeutropeniaBlood and lymphatic system disorders | 31/76 | 22/76 | 38/74 | 55/74 |
| Peripheral sensory neuropathyNervous system disorders | 33/76 | 30/76 | 45/74 | 29/74 |
| AstheniaGeneral disorders | 22/76 | 18/76 | 22/74 | 30/74 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/76 | 16/76 | 26/74 | 17/74 |
| Nail disorderSkin and subcutaneous tissue disorders | 3/76 | 8/76 | 20/74 | 10/74 |
| NeuropathyNervous system disorders | 19/76 | 10/76 | 9/74 | 15/74 |
| Oedema peripheralGeneral disorders | 7/76 | 13/76 | 16/74 | 18/74 |
| Performance status decreasedGeneral disorders | 10/76 | 18/76 | 10/74 | 14/74 |
| LeukopeniaBlood and lymphatic system disorders | 9/76 | 3/76 | 4/74 | 17/74 |
| Age, Continuous(years) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| Mean | 51.7 ± 9.47 | 55.4 ± 9.59 | 53.3 ± 9.14 | 55.4 ± 11.57 | 53.9 ± 10.05 |
| Age, Customized(Participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| >=65 years | 9 | 14 | 10 | 19 | 52 |
| <65 years | 67 | 62 | 64 | 55 | 248 |
| Sex: Female, Male(Participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| Female | 76 | 76 | 74 | 74 | 300 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| White, Non-Hispanic, Non-Latino | 74 | 75 | 74 | 74 | 297 |
| White, Hispanic or Latino | 2 | 1 | 0 | 0 | 3 |
| Weight(Kg) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| Mean | 72.56 ± 12.668 | 73.64 ± 14.670 | 76.24 ± 13.437 | 75.99 ± 14.034 | 74.59 ± 13.742 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| 0 (fully active) | 34 | 33 | 24 | 28 | 119 |
| 1 (restrictive but ambulatory) | 35 | 39 | 45 | 44 | 163 |
| 2 (ambulatory but unable to work) | 7 | 4 | 5 | 2 | 18 |
| 3 (limited self-care) + 4 (completely disabled) | 0 | 0 | 0 | 0 | 0 |
| Menopausal Status(Participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| Pre-menopausal | 26 | 14 | 21 | 12 | 73 |
| Post-menopausal | 49 | 62 | 53 | 60 | 224 |
| Unknown | 1 | 0 | 0 | 2 | 3 |
| Physician Assessment of Sensory Neuropathy(Participants) | ABI-007 300 mg/m^2 q3w | ABI-007 100 mg/m^2 Weekly | ABI-007 150 mg/m^2 | Docetaxel 100 mg/m^2 q3w | Total |
|---|---|---|---|---|---|
| Grade 0 | 67 | 70 | 65 | 67 | 269 |
| Grade 1 | 9 | 6 | 9 | 7 | 31 |
5 further baseline measures are reported on the registry.
Ran from Nov 2005 to primary completion in Mar 2008, 28 months.
Results were first posted in Jul 2013, 5 years 4 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 28 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel